Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 12/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.71 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20022390 | 1.00 | CHRM1 (0.71) | CHRM1CHRM2CHRM3PREPLMNA | |
| SCHEMBL15196405 | 0.87 | CHRM1 (0.53) | CHRM1CHRM2CHRM3PREPHSD11B1 | |
| SCHEMBL19334878 | 0.86 | CHRM1 (0.53) | CHRM1CHRM2CHRM3 | |
| SCHEMBL10106331 | 0.83 | CHRM2 (1.00) | CHRM1CHRM2CHRM3PREPLMNA | |
| SCHEMBL20636193 | 0.83 | CHRM2 (1.00) | CHRM1CHRM2CHRM3PREPLMNA | |
| SCHEMBL641026 | 0.83 | CHRM2 (1.00) | CHRM1CHRM2CHRM3PREPLMNA | |
| SCHEMBL19082743 | 0.83 | CHRM2 (1.00) | CHRM1CHRM2CHRM3PREPLMNA | |
| SCHEMBL22433392 | 0.83 | CHRM2 (1.00) | CHRM1CHRM2CHRM3PREPLMNA | |
| SCHEMBL219188 | 0.83 | CHRM2 (1.00) | CHRM1CHRM2CHRM3PREPLMNA | |
| SCHEMBL1023170 | 0.83 | CHRM2 (1.00) | CHRM1CHRM2CHRM3PREPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202369-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-12 | — | — | US | disclosed |
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | CHRM1 1303/4885CHRM2 987/4885CHRM3 1290/4885 |
| US-10202369-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | CHRM1 1303/4885CHRM2 987/4885CHRM3 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.